Severe (level 3) hypoglycaemia occurrence in a real‐world cohort of adults with type 1 or 2 diabetes mellitus ( iNPHORM , United States)
Authors' conclusion
iNPHORM is one of the first long-term, prospective US-based investigations on level 3 hypoglycaemia epidemiology. Our results underscore the importance of participant-reported data to ascertain its burden. Events were alarmingly frequent, irrespective of diabetes type, and concentrated in a small subsample.
Study context
- Population
- US adults with T1D or insulin- and/or secretagogue-treated T2D, recruited from a probability-based internet panel (2020–2021); T1DM 17%, mean age 51 (SD 14.3) years, male 49.6%≥1 follow-up completed
- Participants
- 978 adults
- Exposure
- T1D vs insulin- and/or secretagogue-treated T2D
- Outcome
- Severe (level 3) hypoglycaemia: absolute frequency, incidence rates and proportions
- Follow-up
- 12-month prospective period
Methodological detailsambidirectional panel survey, US-wide, 12-month, probability-based internet panel
- Ambidirectional panel survey
- US-wide
- 12-month
- Probability-based internet panel
Main finding
As reported in the abstract
≥1 level 3 hypoglycaemia event(s)
P = 0.0404
- Individuals reporting ≥1 event(s), overall
- one-third
Observational data: associations, not effects.
Further findings
Level 3 hypoglycaemia incidence rate · 12-month prospective period · α = 0.0007
P = 0.1352
- Level 3 hypoglycaemia incidence rate — Overall incidence rate (events per person-year (EPPY))
- 5.01 (95% CI 4.15-6.05)
- Level 3 hypoglycaemia requiring non-transport emergency medical services · more common in T2DM; α = 0.0016
- P < 0.0001
Care setting and concentration of events
- Events treated outside the health care system
- 63%
- Events requiring hospitalization
- <5%
- Share of events experienced by <15% of participants
- >90%
Original publication
Severe (level 3) hypoglycaemia occurrence in a real‐world cohort of adults with type 1 or 2 diabetes mellitus ( iNPHORM , United States). Diabetes Obes Metab. Published 13 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →